GlassScriptPhysician profile
Sabina Ali
NPI 1861474348
$3,362.56
in general payments reported to CMS, 2019-2025
34 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $82.51 · 2021: $402 · 2022: $828 · 2023: $859 · 2024: $296 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,373.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $488.11 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $333.15 | 2019-2023 | Prolia, Evenity, Otezla |
| Abbott Laboratories | $308.66 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $240.00 | 2019-2023 | Trulicity, Mounjaro, Emgality |
| Pfizer INC. | $198.74 | 2019-2025 | |
| Abbvie INC. | $197.33 | 2022-2023 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.17 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $135.49 | 2019-2023 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $132.37 | 2019-2023 | |
| Astellas Pharma US INC | $119.10 | 2019-2021 | |
| Exact Sciences Corporation | $106.13 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $96.38 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Corium, LLC | $91.64 | 2023 | Adlarity |
| Dynavax Technologies Corporation | $71.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $69.58 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $67.74 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $66.77 | 2021-2023 | |
| Mylan Specialty L.P. | $58.72 | 2019-2022 | |
| Ucb, INC. | $50.53 | 2021 | |
| Philips North America LLC | $42.20 | 2024 | (Ck6) Holter |
| Merck Sharp & Dohme LLC | $39.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.01 | 2019-2022 | |
| Edwards Lifesciences Corporation | $30.46 | 2022-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| E.R. Squibb & Sons, L.L.C. | $28.13 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $26.38 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.92 | 2022 | |
| Neurocrine Biosciences, INC. | $18.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.67 | 2021 | |
| Insightec,INC | $17.45 | 2023 | Exablate |
| Scilex Pharmaceuticals INC. | $17.00 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.31 | 2019 | |
| Amarin Pharma, INC. | $14.00 | 2019 | |
| Shire North American Group INC | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabina Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.